paclitaxel  (Weleda AG)

Journal: bioRxiv

Article Title: Hyper-responsiveness of cancer stem cells to microenvironmental cues controls metastasis and therapy response through YAP/TAZ/TEAD

doi: 10.1101/2025.03.13.643008

Figure Lengend Snippet: a. Schematic for Paclitaxel treatment. b-c. Effect of Paclitaxel on LM2 lung metastasis size (b) and % CSCs among tumor cells in the lung (c) . Results are median +/− IQ range, n=6-7; Mann-Whitney test d. Number of CSCs/lesion as a function of LM2 lung lesion size in response to Paclitaxel. Results are mean +/− SD for n=1-10 lesions/size bin. ANCOVA test. e. CSC sensor inputs converging on ROCK. f. Effect of combined Paclitaxel + ROCK inhibitor treatment for 3 days on CSCs and nonCSCs in unsorted LM2 cultures in vitro assessed by flow cytometry. Results are mean +/− SD for n=3, Dunnett’s multiple comparison test vs CON. g . Schematic for Paclitaxel + Y27632 treatment in LM2 model. h,i . Effect of therapeutic interventions on median lung lesion size (# tumor cells)/mouse ( h ) or % CSCs/lung ( i ) at endpoint. Results are median +/− IQ range for n=5-6 mice/group; Dunn’s multiple comparisons test vs Paclitaxel. j. Treatment effect on % CSCS as a function of lesion size. Data pooled from 5-6 mice/group, n=8-70 lesions/size bin; Dunn’s multiple comparisons test. k. Treatment effect on % lesions with no CSCs. Fisher’s Exact test for indicated treatment pairs. n= total lesion number as indicated.

Article Snippet: The pharmacologic inhibitor source, dose range and vehicle used for in vitro studies were as follows: TRULI (Selleckchem, E1061, 1-10 µM, DMSO); Defactinib (Selleckchem, S7654, 2.5-12.5 µM, DMSO); Cytochalasin D (Selleckchem, S8184, 0.05-1 µM, DMSO); BMS986020 (Selleckchem, S3572, 1-10 µM, DMSO); AM966 (Selleckchem, S3534, 1-25 µM, DMSO); Y27632 (Selleckchem, 1-10 µM, DMSO); H1152 (Selleckchem, 0.5-5 µM, S6214, DMSO); Fasudil (Selleckchem, S1573, 1-50 µM, DMSO); Torkinib (Selleckchem, S2218, 50-500 nM, DMSO); AICAR (Selleckchem, S1802,0.1-10 µM, PBS); MK3903 (Selleckchem, S8803, 0.5-10 µM, DMSO); GNE7883 (MedChem Express, HY-147214, 0.5-5 µM, DMSO); Paclitaxel (Selleckchem, S1150, 1-25 nM, DMSO)

Techniques: MANN-WHITNEY, In Vitro, Flow Cytometry, Comparison

Journal: BMC Cancer

Article Title: Establishment and characterization of CHC-X1: the third human combined hepatocellular–cholangiocarcinoma cell line

doi: 10.1186/s12885-025-13876-9

Figure Lengend Snippet: Assessment of anti-cancer drug sensitivity in CHC-X1 cells. CHC-X1 cells demonstrated resistance to oxaliplatin ( A ), fluorouracil ( B ), and gemcitabine ( C ), and sensitivity to paclitaxel ( D )

Article Snippet: Gemcitabine was purchased from Jiangsu Haosen Pharmaceutical Group Co., Ltd. and Jiangsu Hengrui Pharmaceutical Co., Ltd. 5-FU was purchased from Shanghai Xudong Haipu Pharmaceutical Co., Ltd., and paclitaxel was purchased from Wuxi Paclitaxel Pharmaceutical Co., Ltd.

Techniques:

Journal: BMC Medicine

Article Title: Lenvatinib plus pembrolizumab compared to carboplatin plus paclitaxel for carboplatin and paclitaxel pretreated, recurrent, or advanced endometrial cancer

doi: 10.1186/s12916-025-03989-0

Figure Lengend Snippet: Baseline characteristics of the lenvatinib plus pembrolizumab and re-challenge PT cohorts, before and after PSM

Article Snippet: We performed a multi-institutional retrospective analysis using de-identified electronic health record database (TriNetX) to compare lenvatinib plus pembrolizumab, carboplatin plus paclitaxel (PT), and doxorubicin outcomes in patients with PT-pretreated, advanced, or recurrent ECs.

Techniques: Irradiation

Journal: BMC Medicine

Article Title: Lenvatinib plus pembrolizumab compared to carboplatin plus paclitaxel for carboplatin and paclitaxel pretreated, recurrent, or advanced endometrial cancer

doi: 10.1186/s12916-025-03989-0

Figure Lengend Snippet: Subgroup analysis of 3-year OS between lenvatinib plus pembrolizumab and re-challenge PT. a Lenvatinib plus pembrolizumab and re-challenge PT with a platinum-free interval of 6 to 12 months. b Lenvatinib plus pembrolizumab and re-challenge PT with a platinum-free interval over 12 months. PT, carboplatin plus paclitaxel. OS, overall survival

Article Snippet: We performed a multi-institutional retrospective analysis using de-identified electronic health record database (TriNetX) to compare lenvatinib plus pembrolizumab, carboplatin plus paclitaxel (PT), and doxorubicin outcomes in patients with PT-pretreated, advanced, or recurrent ECs.

Techniques:

Journal: Nature Communications

Article Title: USP7 V517F mutation as a mechanism of inhibitor resistance

doi: 10.1038/s41467-025-56981-w

Figure Lengend Snippet: a Schematic representation of the generation of USP7-797-resistant variants. CHP-212 cells were exposed to 10 μM USP7-797 for 5 days, refreshing with drug-free media, and repeating for 5 cycles. Six drug-resistant monoclonal cells (R1-R6) were selected. b Dose-response curves of USP7i USP7-797 and FT671 in parental and resistant cells following a 5-day exposure. Left panel, the IC 50 values of USP7-797 and FT671 were determined using SRB assays. Data are presented as mean ± SD ( n = 3 technical replicates; 3 independent experiments). Right panel, the resistance factor (RF) was calculated by comparing the average IC 50 value of the resistant cells to that of the parental cells. c The chemical structure and dose-response curves of another USP7i GNE-6640 in the parental and resistant cells. Cells were treated with GNE-6640 for 5 days, and cell viability was assessed using SRB assays. Data are presented as mean ± SD ( n = 3 technical replicates; 3 independent experiments). d The IC 50 values of MLN4924, KSQ4279, Adriamycin, Bortezomib, TAXOL, and VCR in parental and resistant cells were determined using SRB assays following 3 days exposure. Data are presented as mean ± SD ( n = 3 technical replicates; 3 independent experiments).

Article Snippet: FT671, GNE-6640, and Taxol were purchased from MedChemExpress (Monmouth Junction, NJ, USA).

Techniques:

Journal: bioRxiv

Article Title: Tubulin isotypes polymerise into sectioned microtubules that locally regulate protein binding

doi: 10.1101/2025.03.12.642813

Figure Lengend Snippet: A) Experimental setup. Sequential flushes of tubulin isotypes imaged by IRM, allowing discrimination of isotypes, after which fluorescent OPTN or TPPP1 is added, imaged using TIRF microscopy and analysed. B,C) Taxol-stabilized α1β3 and α1β4 single-isotype-microtubules are sequentially flushed in and later B) TPPP1 or C) OPTN is imaged, and fluorescence density quantified (right). D,E) GDP lattice α1β3 and α1β4 single isotype microtubules are sequentially flushed in and imaged by IRM. Later D) TPPP1 or E) OPTN is imaged, and fluorescence density is quantified from the whole microtubule (right). Cyan arrows point to the α1β4 single isotype. Scale bars 4 µm. N= 3 for each experiment in figure, **** is p<0.0001, Student t test for each plot in figure.

Article Snippet: Microtubules were polymerized from HeLa tubulin or recombinant human tubulin or pig brain tubulin in the BRB80 (80 mM PIPES, 1 mM EGTA, 1 mM MgCl 2 , pH 6.9) supplemented with 1 mM MgCl 2 and 1 mM GTP (Jena Bioscience, Jena, Germany) for 30 minutes at 37 ºC prior to centrifugation at 18.000 x g for 30 min in a Microfuge 18 Centrifuge (Beckman Coulter) and resuspension of the microtubule pellet in BRB80 supplemented with 10 µM taxol (Sigma Aldrich, T7191) (BRB80T).

Techniques: Microscopy, Fluorescence

Journal: bioRxiv

Article Title: Tubulin isotypes polymerise into sectioned microtubules that locally regulate protein binding

doi: 10.1101/2025.03.12.642813

Figure Lengend Snippet: A) IRM images of serial flushes of 12 and 14 protofilament microtubules, TPPP1 on microtubules, orange arrows indicate 14 protofilament microtubules. B) Analysis of TPPP1 signal on 12 and 14 protofilaments, p=0.1392. C) IRM images of serial flushes of 12/14 protofilament microtubules, OPTN imaged on microtubules, orange arrows indicate 14 protofilament microtubules. D) Analysis of OPTN signal on 12 and 14 protofilament number microtubules, p<0.0001. E) IRM images of serial flushes of taxol-stabilized α1β3 followed by α1β4, OPTN on the microtubules, cyan arrow points to α1β4 isotype. F) Analysis of IRM signal of α1β4- and α1β3-microtubules done in parallel, with quantification of OPTN signal on the same microtubules, p<0.0001. G) IRM image of mixed-isotype microtubules, OPTN on mixed isotype microtubules showing high-OPTN and low-OPTN sections. H) Analysis of IRM density on OPTN recognized section and low-OPTN section on mixed-isotype microtubules, ** means p=0.0012, Scale bars 4 µm. N= 3 for each experiment in figure, Student t test for each plot in figure. 12 pf: 12 protofilaments, 14 pf: 14 protofilaments.

Article Snippet: Microtubules were polymerized from HeLa tubulin or recombinant human tubulin or pig brain tubulin in the BRB80 (80 mM PIPES, 1 mM EGTA, 1 mM MgCl 2 , pH 6.9) supplemented with 1 mM MgCl 2 and 1 mM GTP (Jena Bioscience, Jena, Germany) for 30 minutes at 37 ºC prior to centrifugation at 18.000 x g for 30 min in a Microfuge 18 Centrifuge (Beckman Coulter) and resuspension of the microtubule pellet in BRB80 supplemented with 10 µM taxol (Sigma Aldrich, T7191) (BRB80T).

Techniques: